Want to see CAH full AI Analyst Report?
CAH Stock Chart & Stats
$228.03
$2.05(0.91%)
At close: 4:00 PM EDT
$228.03
$2.05(0.91%)
Day’s Range― - ―
52-Week Range$137.75 - $243.21
Previous CloseN/A
Volume1.47M
Average Volume (3M)2.27M
Market Cap
$53.18B
Enterprise Value$55.01K
Total Cash (Recent Filing)$3.94B
Total Debt (Recent Filing)$8.92B
Price to Earnings (P/E)35.1
Beta0.33
Next Earnings
Aug 11, 2026EPS Estimate
2.42Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)6.56
Shares Outstanding234,205,860
10 Day Avg. Volume2,156,172
30 Day Avg. Volume2,265,102
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)-14.56
Price to Sales (P/S)0.18
P/FCF Ratio21.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$254.44Price Target Upside11.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)12.08
Revenue Forecast (FY)$275.63B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent, large operating and free cash flow provides durable funding for operations, capex, buybacks and debt paydowns. Over 2–6 months this supports financial flexibility and capital returns even if margins remain thin, and cushions the business versus cyclical working capital swings.
Upgraded Guidance & ExecutionManagement raised and narrowed FY2026 EPS and free‑cash‑flow guidance based on recent operational strength. This indicates sustainable execution improvements, better cost control and higher confidence in recurring profitability drivers rather than a one‑off beat.
Diversified Growth BusinessesExpansion into Specialty, At‑Home Solutions, Theranostics and logistics creates higher‑growth, higher‑margin tails that diversify revenue away from commodity pharma distribution. Over months this reduces reliance on low‑margin volumes and can sustainably lift segment profit contribution.
Bears Say
Negative Equity & LeveragePersistently negative equity and sizable gross debt materially weaken the balance sheet and constrain financial flexibility. Even with strong cash flow, negative equity raises refinancing and covenant risks and reduces the company’s ability to absorb shocks or pursue larger acquisitions.
Structurally Low MarginsCardinal operates in high‑volume, low‑margin distribution where small pricing, mix or cost moves compress profits. Sustainable margin uplift requires structural mix shifts; otherwise earnings and cash generation remain highly sensitive to reimbursement, pricing and cost pressures.
Regulatory, Tariff & Impairment RisksTariff exposure, uncertain refunds and recent goodwill impairment point to policy and valuation risks that can recur. Regulatory outcomes and tariff timing can materially affect cash and segment profit, creating durable uncertainty for planning and forecasting over upcoming quarters.
Cardinal Health News
CAH FAQ
What was Cardinal Health’s price range in the past 12 months?
Cardinal Health lowest stock price was $137.75 and its highest was $243.21 in the past 12 months.
What is Cardinal Health’s market cap?
Cardinal Health’s market cap is $53.18B.
When is Cardinal Health’s upcoming earnings report date?
Cardinal Health’s upcoming earnings report date is Aug 11, 2026 which is in 9 days.
How were Cardinal Health’s earnings last quarter?
Cardinal Health released its earnings results on Apr 30, 2026. The company reported $3.17 earnings per share for the quarter, beating the consensus estimate of $2.795 by $0.375.
Is Cardinal Health overvalued?
According to Wall Street analysts Cardinal Health’s price is currently Undervalued.
Does Cardinal Health pay dividends?
Cardinal Health pays a Quarterly dividend of $0.516 which represents an annual dividend yield of 0.89%. See more information on Cardinal Health dividends here
What is Cardinal Health’s EPS estimate?
Cardinal Health’s EPS estimate is 2.42.
How many shares outstanding does Cardinal Health have?
Cardinal Health has 234,205,860 shares outstanding.
What happened to Cardinal Health’s price movement after its last earnings report?
Cardinal Health reported an EPS of $3.17 in its last earnings report, beating expectations of $2.795. Following the earnings report the stock price went down -4.901%.
Which hedge fund is a major shareholder of Cardinal Health?
Currently, no hedge funds are holding shares in CAH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardinal Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$254.44 (11.58% Upside)
$254.44 (11.58% Upside)
Blogger Sentiment
Bullish
CAH Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 788.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.47%
12-Months-Change
Fundamentals
Return on Equity
0.89%
Trailing 12-Months
Asset Growth
13.67%
Trailing 12-Months
Company Description
Cardinal Health
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
CAH Company Deck
CAH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted broad-based operational strength: solid top-line growth, outsized EPS improvement, robust free cash flow generation, meaningful outperformance in Specialty and other growth businesses, and a raised, narrowed FY26 outlook. Challenges noted include a $184M goodwill impairment for Navista, tariff-related pressure in the GMPD business with uncertain refunds (paid ~ $200M to date), higher headline SG&A and rising interest costs, and revenue mix headwinds from IRA/WAC adjustments and GLP-1 moderation. On balance the company emphasized durable fundamentals, disciplined capital deployment (including $1B of buybacks), successful integration of acquisitions and confidence in long-term targets.View all CAH earnings summariesCAH Revenue Breakdown
91.94% Pharmaceutical and Specialty Solutions
5.68% Global Medical Products and Distribution
2.42% Other
-0.04% Corporate

CAH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$254.44
▲(11.58% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
0.25% Insiders
22.70% Mutual Funds
2.98% Other Institutional Investors
44.32% Public Companies and Individual Investors











